SMS Pharmaceuticals receives EIR from USFDA for API facility in Andhra Pradesh

12 Mar 2020 Evaluate

SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected the said facility during the period January 13, 2020 to January 17, 2020. This facility predominantly caters regulated markets including USA.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

316.70 -7.20 (-2.22%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×